Results from a phase 2 study of sonepcizumab were published in the journal Cancer this week and showed encouraging overall survival and a favourable safety profile, although the study did not reach its primary endpoint of 2-month progression-free survival (PFS). However, despite the modest PFS (mean of 2.2 months), the encouraging overall survival warrant further investigation of sonepcizumab in combination with immunotherapies and vascular endothelial growth factor (VEGF) inhibitors. Read more here
NEWS
Sonepcizumab shows promise for metastatic kidney cancer
Clinical Trials
1 minute read
Related Posts
Clinical Trials
Conference Reports
Homepage Feature
Treatment Options
5 minutes read
ESMO Highlights from the International Kidney Cancer Coalition
Note: The following summary was prepared by patient advocates for the benefit of patient organisations who focus on kidney cancer. While this summary has been medically reviewed, the information contained herein is based upon public data shared at this meeting and is not intended to be exhaustive. Patients should ask their physician about any information […]
Clinical Trials
1 minute read
Cabozantinib superior to sunitinib as a first-line therapy for advanced kidney cancer
Results from the phase II CABOSUN clinical trial, showing cabozantinib to be superior to sunitinib as first-line treatment for advanced kidney cancer, were presented at the European Society for Medical Oncology (ESMO) congress in Copenhagen this week. Read more
Clinical Trials
Homepage Feature
1 minute read
Sunitinib shown to improve disease-free survival in people with kidney cancer
Results from the S-TRAC study were presented at the European Society of Medical Oncology. (ESMO) congress in Copenhagen this week. The results show that sunitinib improved disease-free survival in patients with localised kidney cancer that had been surgically removed; a group considered high-risk for relapse. Read more